AstraZeneca

AstraZeneca, a British-Swedish pharmaceutical giant, is currently making headlines due to significant developments in its global operations. The company is investing $15 billion in China by 2030, expanding manufacturing and R&D, signaling strengthened Sino-UK commercial ties. This investment comes shortly after scaling back UK expansion plans. However, AstraZeneca faces challenges, including fraud charges against a former China executive, Leon Wang, related to medical insurance, illegal trading, and data collection. Simultaneously, experts warn about a shrinking pipeline of new drugs to combat superbugs, with large pharma companies' projects decreasing by 35% in the last five years. Despite these challenges, AstraZeneca's CEO, Pascal Soriot, received a 6.4% pay rise, bringing his total remuneration to £17.7m. These events highlight AstraZeneca's strategic focus on the Chinese market, its commitment to innovation, and the complexities of operating in a global pharmaceutical landscape.